KNSA

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares

43.16

USD

KNSA Earnings Reports

Positive Surprise Ratio

KNSA beat 18 of 30 last estimates.

60%

Next Report

Date of Next Report

Feb 16, 2026

Estimate for Q4 25 (Revenue/ EPS)

$197.87M

$0.35

Implied change from Q3 25 (Revenue/ EPS)

+9.41%

+52.17%

Implied change from Q4 24 (Revenue/ EPS)

+61.48%

-391.67%

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares earnings per share and revenue

On Oct 28, 2025, KNSA reported earnings of 0.23 USD per share (EPS) for Q3 25, missing the estimate of 0.32 USD, resulting in a -30.26% surprise. Revenue reached 180.85 million, compared to an expected 170.71 million, with a 5.95% difference. The market reacted with a -2.88% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 9 analysts forecast an EPS of 0.35 USD, with revenue projected to reach 197.87 million USD, implying an increase of 52.17% EPS, and increase of 9.41% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Arrowhead Research Corporation

Report Date

Feb 05, 2026 For Q1 26

Estimate

$0.25

Actual

$0.22

Surprise

-14.76%

Immunovant, Inc. Common Stock

Report Date

Feb 06, 2026 For Q3 26

Estimate

-$0.72

Actual

-$0.61

Surprise

+16.27%

Adaptive Biotechnologies Corporation Common Stock

Report Date

Feb 05, 2026 For Q4 25

Estimate

-$0.18

Actual

-$0.09

Surprise

+51.33%

Amgen Inc

Report Date

Feb 03, 2026 For Q4 25

Estimate

$4.82

Actual

$5.29

Surprise

+9.56%

Bristol-Myers Squibb Co.

Report Date

Feb 05, 2026 For Q4 25

Estimate

$1.12

Actual

$1.26

Surprise

+11.88%

GSK plc - ADR

Report Date

Feb 04, 2026 For Q4 25

Estimate

$0.23

Actual

$0.49

Surprise

+111.36%

Biogen Inc. Common Stock

Report Date

Feb 06, 2026 For Q4 25

Estimate

$1.62

Actual

$1.99

Surprise

+22.39%

Illumina Inc

Report Date

Feb 05, 2026 For Q4 25

Estimate

$1.24

Actual

$1.35

Surprise

+8.01%

QIAGEN N.V.

Report Date

Feb 04, 2026 For Q4 25

Estimate

$0.64

Actual

$0.62

Surprise

-3.32%

Bio-Techne Corp.

Report Date

Feb 04, 2026 For Q2 26

Estimate

$0.44

Actual

$0.46

Surprise

+3.95%

FAQ

What were Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares reported EPS of $0.23, missing estimates by -30.26%, and revenue of $180.85M, 5.95% above expectations.

How did the market react to Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's Q3 2025 earnings?

The stock price moved down -2.88%, changed from $40.60 before the earnings release to $39.43 the day after.

When is Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares expected to report next?

The next earning report is scheduled for Feb 16, 2026.

What are the forecasts for Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's next earnings report?

Based on 9 analysts, Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares is expected to report EPS of $0.35 and revenue of $197.87M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.